文献速递乳腺癌放疗放疗物理与技术

乳腺癌乳房切除术后质子放疗后乳房重建并发症

Breast Reconstruction Complications After Postmastectomy Proton Radiation Therapy for Breast Cancer.
PubMed 文献 · Adv Radiat Oncol · 2023-10-14

前瞻性质子登记研究纳入2013至2021年68例乳房切除术后质子放疗(50/50.4 Gy±胸壁补量)且同期乳房重建的乳腺癌患者,共73程放疗。中位随访42.1个月,主要重建并发症(需手术干预)发生率为12.3%,3年无主要重建并发症生存率为86.9%,重建完全失败3例(4.1%)。各重建类型间主要并发症发生率相似。

要点

  • 乳房切除术后质子放疗期间乳房重建患者主要重建并发症发生率为12.3%。
  • 3年无主要重建并发症生存率为86.9%,重建完全失败仅3例(4.1%)。
  • 各重建类型间主要并发症发生率相似,体重指数升高趋势与主要并发症相关(HR 1.07,95%CI 0.99-1.16,P=0.10)。

核心结论

  • 接受乳房切除术后质子放疗的乳房重建患者主要并发症需手术干预的发生率为12.3%,重建完全丢失罕见。
  • 各重建类型间主要重建并发症发生率相似;在本中心实践中,为美容修整而行的常规修整手术较常见。

研究设计与样本

  • 前瞻性质子登记研究,纳入2013至2021年68例接受乳房切除术后质子放疗且同期行乳房重建的乳腺癌女性,共73程放疗。
  • 放疗剂量为50/50.4 Gy±胸壁补量;重建方式包括即刻自体皮瓣、组织扩张器或假体。
  • 主要重建并发症定义为需手术干预的并发症;重建完全失败定义为需手术移除重建物的主要并发症;常规修整定义为塑形改善重建美观的整形手术。
  • 采用Kaplan-Meier法评估疾病结局和主要重建并发症,Cox回归评估主要重建并发症的预测因素。

主要发现

  • 中位随访42.1个月,中位年龄47岁;56程(76.7%)采用笔形束扫描质子放疗。
  • 73个重建中,放疗时皮瓣29个(39.7%)、假体30个(41.1%)、组织扩张器14个(19.2%)。
  • 常规修整20例(27.4%);主要重建并发症9例(12.3%),其中假体5例、皮瓣2例、组织扩张器2例,发生距质子放疗开始的中位时间为29个月。
  • 3年无主要重建并发症生存率为86.9%;主要重建并发症中重建完全失败3例(4.1%)。
  • 导致主要重建并发症的并发症包括包膜挛缩5例、脂肪坏死2例、感染2例。

关键数值与推荐

  • 主要重建并发症定义为需手术干预的并发症;重建完全失败定义为需手术移除重建物的主要重建并发症。
  • 放疗剂量为50/50.4 Gy±胸壁补量。

临床怎么用

  • 原文未据此给出推荐。
  • 作者报告接受乳房切除术后质子放疗的乳房重建患者主要并发症需手术干预的发生率为12.3%,重建完全丢失罕见。
  • 作者报告各重建类型间主要重建并发症发生率相似;在本中心实践中,为美容修整而行的常规修整手术较常见。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Our purpose was to report complications requiring surgical intervention among patients treated with postmastectomy proton radiation therapy (PMPRT) for breast cancer in the setting of breast reconstruction (BR). METHODS AND MATERIALS: Patients enrolled on a prospective proton registry who underwent BR with immediate autologous flap, tissue expander (TE), or implant in place during PMPRT (50/50.4 Gy +/- chest wall boost) were eligible. Major reconstruction complication (MRC) was defined as a complication requiring surgical intervention. Absolute reconstruction failure was an MRC requiring surgical removal of BR. A routine revision (RR) was a plastic surgery refining cosmesis of the BR. Kaplan-Meier method was used to assess disease outcomes and MRC. Cox regression was used to assess predictors of MRC. RESULTS: Seventy-three courses of PMPRT were delivered to 68 women with BR between 2013 and 2021. Median follow-up was 42.1 months. Median age was 47 years. Fifty-six (76.7%) courses used pencil beam scanning PMPRT. Of 73 BR, 29 were flaps (39.7%), 30 implants (41.1%), and 14 TE (19.2%) at time of irradiation. There were 20 (27.4%) RR. There were 9 (12.3%) MRC among 5 implants, 2 flaps, and 2 TE, occurring a median of 29 months from PMPRT start. Three-year freedom from MRC was 86.9%. Three (4.1%) of the MRC were absolute reconstruction failure. Complications leading to MRC included capsular contracture in 5, fat necrosis in 2, and infection in 2. On univariable analysis, BR type, boost, proton technique, age, and smoking status were not associated with MRC, whereas higher body mass index trended toward significance (hazard ratio, 1.07; 95% CI, 0.99-1.16; P = .10). CONCLUSIONS: Patients undergoing PMPRT to BR had a 12.3% incidence of major complications leading to surgical intervention, and total loss of BR was rare. MRC rates were similar among reconstruction types. Minor surgery for RR is common in our practice.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Berlin E, Yegya-Raman N, Hollawell C, et al. Breast Reconstruction Complications After Postmastectomy Proton Radiation Therapy for Breast Cancer. Adv Radiat Oncol. 2023. PMID: 38495035. doi:10.1016/j.adro.2023.101385

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。